SAN ANTONIO - Two analyses of first-line ribociclib (Kisqali) trials showed ... Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Bayer, ...
News
- Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site | MedPage Today
- Ambrx Biopharma Inc. Presents Data From Ongoing ACE-Breast-01 Phase 1 Clinical Study ...
Presents Data From Ongoing ACE-Breast-01 Phase 1 Clinical Study Of ARX788 At San Antonio Breast Cancer Symposium; Co. Reports 'ARX788 demonstrated ...
- BriaCell Summarizes Clinical Data Poster Presented at the 2021 San ... - Investing News Network
BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other ...
- Data confirm efficacy of pembrolizumab regimen for certain breast cancer subgroups - Healio
... patients with inoperable or metastatic triple-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.
- BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer ...
(Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies ...